News
CRDF
3.520
-21.43%
-0.960
AEON Biopharma, Allarity Therapeutics, ModivCare among healthcare movers
Seeking Alpha · 2d ago
AEON, SGBX and APVO among pre-market losers
On the Move AEON, SGBX and APVO among pre-market losers. Sprout Social, Expedia Group and Expedia are among the day's losers. AEON Biopharma announces preliminary top-line results for ABP-450 in the treatment of chronic migraine.
Seeking Alpha · 2d ago
Cardiff Oncology (CRDF) Gets a Buy from Piper Sandler
TipRanks · 2d ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
Helius Medical Tech (NASDAQ:HSDT) shares increased by 48.9% to $3.96 during Friday's pre-market session. Owens & Minor (NYSE:OMI) stock increased by 13.99% in the same session. Vaxxinity shares moved upwards by 41.17% as the company's Q1 earnings report came out today.
Benzinga · 2d ago
CRDF Stock Earnings: Cardiff Oncology Beats EPS, Beats Revenue for Q1 2024
Cardiff Oncology reported results for the first quarter of 2024. The company reported earnings per share of -22 cents and revenue of $205,000. This was 310% better than the analyst estimate of -25 cents for the same period.  Cardiff oncology has a market value of $1.2 billion.
Investorplace · 2d ago
Cardiff Oncology, Inc. Quarterly Report: Financial Statements and Analysis
Press release · 2d ago
Cardiff Oncology Inc reports results for the quarter ended in March - Earnings Summary
Cardiff Oncology Inc reports results for the quarter ended in March. The company reported a quarterly adjusted loss of 22 cents per share. Revenue rose 147% to $205.00 thousand from a year ago. The average analyst rating on the company's shares is "buy"
Reuters · 2d ago
Cardiff Oncology Q1 2024 GAAP EPS $(0.22) Beats $(0.25) Estimate, Sales $205.000K Beat $55.000K Estimate
Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $0.22 per share. The company reported quarterly sales of $205.000 thousand. This is a 146.99 percent increase over sales of the same period last year. The quarterly losses beat the analyst consensus estimate by 12 percent.
Benzinga · 2d ago
12 Health Care Stocks Moving In Thursday's After-Market Session
Twist Bioscience (NASDAQ:TWST) stock increased by 14.1% to $36.51 during Thursday's after-market session. The company's, Q2 earnings came out today. Tandem Diabetes Care's stock moved upwards by 12.25% as the company's market cap stands at $2.6 billion. NKGen Biotech shares rose 8.33% and Jaguar Health shares increased by 13.91% during the day.
Benzinga · 2d ago
Cardiff Oncology GAAP EPS of -$0.22 beats by $0.03, revenue of $0.2M beats by $0.14M
Earnings News Cardiff Oncology GAAP EPS of -$0.22 beats by $0.03, revenue of $ 0.2M beats by £0.14M. The company believes its current cash resources are sufficient to fund its operations into Q3 of 2025.
Seeking Alpha · 2d ago
*Cardiff Oncology 1Q Rev $205,000 >CRDF
Dow Jones · 2d ago
CARDIFF ONCOLOGY INC: CASH AND EQUIVALENTS OF $67 MLN AS OF MARCH 31, 2024, PROJECTED RUNWAY INTO Q3 2025
Reuters · 2d ago
Press Release: Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update
Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update. Cash and equivalents of $67 million as of March 31, 2024, projected runway into Q3 2025. In RAS-mutated mCRC, clinical data from ONSEMBLE trial demonstrated strong efficacy signal in bev naïve patients. Company is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies.
Dow Jones · 2d ago
Press Release: Cardiff Oncology Reports First -2-
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLk1 inhibitor being evaluated in combination with standard of care. Cardiff oncology's forward-looking statements are subject to risks and uncertainties.
Dow Jones · 2d ago
*Cardiff Oncology 1Q Loss/Shr 22c >CRDF
Dow Jones · 2d ago
Weekly Report: what happened at CRDF last week (0422-0426)?
Weekly Report · 6d ago
Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update
Cardiff Oncology, Inc. Plans to release financial results for the first quarter ended March 31, 2024. Management will hold a conference call on Thursday, May 2. The company is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers.
Barchart · 04/25 15:05
Weekly Report: what happened at CRDF last week (0415-0419)?
Weekly Report · 04/22 11:56
Weekly Report: what happened at CRDF last week (0408-0412)?
Weekly Report · 04/15 11:46
Election Year Encore: Can 2020’s Top 7 Stock Winners Repeat Their Performance in 2024?
Investorplace · 04/09 20:30
More
Webull provides a variety of real-time CRDF stock news. You can receive the latest news about Cardiff Oncology Inc through multiple platforms. This information may help you make smarter investment decisions.
About CRDF
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has five ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, one trial (CRDF-001) in second-line treatment in patients with mPDAC, and three investigator-initiated trials in first line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.